Home > Healthcare > Pharmaceuticals > Finished Drug Form > Polycystic Ovarian Syndrome Treatment Market

Polycystic Ovarian Syndrome Treatment Market Trends

Report ID: GMI9770
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Polycystic Ovarian Syndrome Treatment Market Trends

The rising incidence of polycystic ovarian syndrome (PCOS) among women of reproductive age is significantly driving the market.
This condition, characterized by hormonal imbalances, irregular menstrual cycles, and ovarian cysts, is increasingly being diagnosed due to heightened awareness and improved diagnostic techniques.
For instance, the World Health Organization (WHO) data suggests that approximately 116 million women (3.4%) are affected by PCOS globally. Further, up to 70% of affected women remain undiagnosed worldwide.
As more women experience the symptoms and complications associated with PCOS, the demand for effective treatment options, including medication, lifestyle interventions, and assisted reproductive technologies, has surged.
This growing patient population necessitates advancements in therapeutic solutions, fostering innovation and expansion within the market.
Additionally, the increasing focus on women's health and the socio-economic impacts of untreated PCOS further amplify the need for comprehensive treatment strategies, thereby propelling market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global polycystic ovarian syndrome treatment industry was valued at USD 5.6 billion in 2023 and is anticipated to register 5.8% CAGR between 2024 and 2032 due to rising awareness and diagnosis along with higher incidence of obesity and sedentary lifestyle.

The polycystic ovarian syndrome (PCOS) treatment market size from insulin-sensitizing agents segment accounted for USD 1.3 billion, driven by the widespread recognition of insulin resistance and increasing awareness among healthcare providers and patients.

North America market size is anticipated to reach USD 3.5 billion by 2032 due to the high prevalence of PCOS, robust healthcare infrastructure and widespread access to advanced medical technologies.

Abbott Laboratories, AbbVie Plc, Addex Therapeutics Ltd., AstraZeneca PLC, Bayer AG, Bristol-Myer Squibb Company, Ferring BV, Johnson and Johnson, Merck KGaA, Mylan N.V, Novartis AG, and Pfizer Inc. among others.